Financial Performance Summary

Wockhardt Limited reported unaudited financial results for the quarter ended 30th June, 2026 (Q1 FY27), showing significant improvement across key metrics.

Key Financial Metrics

| Metric | Q1 FY27 | Q1 FY26 | Q4 FY26 |

| Total Revenue (Rs Cr) | 929 | 738 | 965 |

| EBITDA before R&D (Rs Cr) | 222 | 128 | 224 |

| EBITDA before R&D % to Sales | 23.8% | 17.4% | 23.2% |

| R&D Expenditure (Rs Cr) | 34 | 27 | 28 |

| R&D % to Sales | 3.6% | 3.7% | 2.9% |

| EBITDA (Rs Cr) | 188 | 101 | 196 |

| EBITDA Margins % | 20.2% | 13.7% | 20.3% |

| Exceptional Items (Rs Cr) | - | (97) | 22 |

| Profit Before Tax (Rs Cr) | 116 | (109) | 189 |

| Profit After Tax (Rs Cr) | 107 | (108) | 164 |

| PAT Margins % | 11.5% | -14.6% | 17.0% |

Performance Analysis

  • Revenue growth of 26% YoY (Rs 929 Cr vs Rs 738 Cr in Q1 FY26)
  • EBITDA growth of 86% YoY (Rs 188 Cr vs Rs 101 Cr in Q1 FY26)
  • Profit before tax of Rs 116 Cr compared to loss of Rs 109 Cr in previous year
  • PAT of Rs 107 Cr compared to loss of Rs 108 Cr in Q1 FY26
  • PAT margins improved to 11.5% from negative 14.6% YoY

Regional Performance Breakdown

| Region | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | Q4 FY26 | Currency |

| India Branded Business | 156 | 129 | 112 | INR Cr |

| India-Others | 46 | 49 | 79 | INR Cr |

| Emerging Market | 263 | 161 | 320 | INR Cr |

| UK | 27 | 27 | 29 | GBP Mn |

| Others | 11 | 9 | 10 | Euro Mn |

| Total Revenue | 929 | 738 | 965 | INR Cr |

Regional Highlights

  • India Branded Business: Rs 156 crore in Q1 FY27, growth of 21% YoY, driven by Diabetic therapy, NCE (EMROK) and Regenerative Derma segment
  • UK region: Rs 343 crore in Q1 FY27, growth of 10% YoY
  • Emerging Markets region: Rs 263 crore in Q1 FY27, growth of 64% YoY, driven by Biotech Insulin segment and Latam operations
  • Irish region: Rs 64 crore in Q1 FY27, growth of 28% YoY

Biosimilar Business Performance

  • Overall Biotech operations: Rs 236 crore, growth of 112% vs Q1 FY26
  • Emerging Market biotech segment: ~146% growth on Q1 FY26
  • Strategic business partnerships and new deal acquisitions in Brazil, Thailand, Egypt, Algeria and LATAM
  • India Biotech operations continues double-digit growth
  • Upcoming launch of Insulin analogs over next few years

Novel Antibiotics Update

Five Novel Antibiotics completed Phase 3 Clinical Trials successfully: Emrok®, Emrok O®, Miqnaf®, Zaynich® and Foviscu®

ZAYNICH®

  • US FDA Approval: May 30, 2026 for treatment of cUTI including Pyelonephritis (1st ever India-discovery and developed drug approved by US FDA)
  • India Approval: May 28, 2026 for treatment of cUTI including Pyelonephritis
  • EMA Review: Marketing Authorization Application progressing, dossier adequate for review for cUTI, cIAI, HAP/VAP and bloodstream infections
  • CDSCO Approval: Subject Expert Committee approved clinical data on March 10, 2026; Full approval after CMC data review expected by Q3 FY27

EMROK® / EMROK O®

  • Growth rate of 29% vs previous year Q1 FY27
  • Addressing difficult-to-manage Gram-positive infections including bone and joint infections, diabetic foot infections, and pneumonia
  • On track to become leading brands in anti-MRSA therapy segment
  • Approval received for EMROK O and EMROK injection in Uganda

MIQNAF® NAFITHROMYCIN

  • Approved and launched in India
  • Removal of "supply condition" by DCGI facilitates marketing access to wider patient population
  • Field force deployed for ease of drug access
  • Increasing clinical acceptance due to comprehensive pathogen coverage and shorter therapy course

FOVISCU® (WCK 4282)

  • India Phase 3 Clinical Trial completed successfully
  • NDA Filing planned during Q3 FY27
  • Combined Phase 2 and Phase 3 program with 324 hospitalized cUTI and AP patients
  • 51% of Enterobacterales isolates were ESBL-positive, 34% of Gram negatives resistant to cefepime

Product Pipeline Update

  • 12 Filings, 9 Approvals and 5 launches in International Business
  • Biosimilars: 1 Filing and 3 Approvals
  • NCE: 1 Filing & 2 Approvals

Intellectual Property

  • 1 Patent filed during Q1 FY27
  • Cumulative filings: 3291 patents
  • Company holds: 859 patents

Company Overview

Wockhardt is a research-based Global Pharmaceutical and Biotech company with focus on Anti-bacterial drugs effective against superbugs. The company has:

  • QIDP Status (Qualified Infectious Disease Product) for 6 Anti-bacterial discovery programmes (3 Gram Negative, 3 Gram Positive)
  • ~3200 employees across 27 nationalities
  • Presence in UK, Ireland, Switzerland, France, Mexico, Russia and other countries
  • Manufacturing and research facilities in India and UK
  • Manufacturing facility in Ireland
  • 78% of global revenues from international businesses